Glutamate and mitochondria: Two prominent players in the oxidative stress-induced neurodegeneration

Current Alzheimer Research

Volumn 13, Issue 2, 2016, Pages 174-184

  Cassano, Tommaso ^a   Pace, Lorenzo ^a   Bedse, Gaurav ^b   Lavecchia, Angelo Michele ^b   De Marco, Federico ^c   Gaetani, Silvana ^b   Serviddio, Gaetano ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alzheimer disease; Glutamate; Mitochondria; Oxidative stress; Parkinson disease

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; GLUTAMIC ACID; NEUROTRANSMITTER;

ALZHEIMER DISEASE; ARTICLE; BRAIN MITOCHONDRION; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; DEGENERATIVE DISEASE; GLIA CELL; HUMAN; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 84959377278     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666151218132725     Document Type: Article

References (176)

1. Harman D. The aging process. Proc Natl Acad Sci USA 78: 7124-7128 (1981).
2. Di Carlo M, Giacomazza D, Picone P, Nuzzo D, San Biagio PL. Are oxidative stress and mitochondrial dysfunction the key players in the neurodegenerative disease?. Free Radic Res 46(11): 1327-1338 (2012).
3. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58(4): 495-505 (2005).
4. D’Aureaux B, Toledano MB. ROS as a signalling molecules: mechanisms taht generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824 (2007).
5. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313 (2007).
6. Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann NY Acad Sci 1147: 37-52 (2008).
7. Yu BP. Cellular defenses against damage from reactive oxygen species. Biol Rev 74: 139-162 (1994).
8. Uday B, Dipak D, Ranajit BK. Reactive oxygen species: Oxidative damage and pathogenesis. Curr Sci 77: 658-666 (1990).
9. Yun-Zhong F, Sheng Y, Guoyao WU. Free radicals, antioxidants, and nutrition. Nutrition 18: 872-879 (2002).
10. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7: 65-74 (2009).
11. Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G et al. Oxidative stress signaling in Alzheimer disease. Curr Alzheimer Res 5(6): 525-532 (2008).
12. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658 (2006).
13. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep 17(1): 3-8 (1997).
14. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112(4): 481-490 (2003).
15. Geddes JW, Sullivan PG. Special Issue: Mitochondria and Neurodegeneration. Exp Neurol 218(2): 169-70 (2009).
16. Schinder AF, Olson EC, Spitzer NC, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16(19): 6125-6133 (1996).
17. Mailly F, Marin P, Israel M, Glowinski J, Premont J. Increase in external glutamate and NMDA receptor activation contribute to H2O2-induced neuronal apoptosis. J Neurochem 73(3): 1181-1188 (2009).
18. Navarro A, Boveris A. Brain mitochondrial dysfunction and oxidative damage in Parkinson’s disease. J Bioenerg Biomembr 41: 517-521 (2009).
19. Melo A, Monteiro L, Lima RM, Oliveira DM, Cergueira MD, El-Bacha RS. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev 2011: 467180 (2011).
20. Radak Z, Zhao Z, Goto S, Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol Aspects Med 32: 305-315 (2011).
21. Sultana R, Perluigi M, Butterfield DA. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med 62: 157-169 (2013).
22. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann NY Acad Sci 1144: 97-112 (2008).
23. Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 23: 613-643 (2007).
24. Martin SJ, Grimwood PD, Morris RGM. Synaptic Plasticity and Memory: An Evaluation of the Hypothesis. Ann Rev Neurosci 23: 649-711 (2000).
25. Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson’s disease. Front Neurosci 8: 113 (2014).
26. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 17: 31-108 (1994).
27. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322 (2010).
28. Wright A, Vissel B. The essential role of AMPA receptor GluR2sub-unit RNA editing in the normal and diseased brain. Front Mol Neurosci 5: 34 (2012).
29. Wiltgen BJ, Royle GA, Gray EE, Abdipranoto A, Thangthaeng N, Jacobs N, et al. A role for calcium-permeable AMPA receptors in synaptic plasticity and learning. PloS One 5: 12818 (2010).
30. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motorcircuit. Nat Rev Neurosci 6: 787-798 (2005).
31. Kuwajima M, Dehoff MH, Furuichi T, Worley PF, Hall RA, Smith Y. Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion. J Neurosci 27: 6249-6260 (2007).
32. Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 100(4): 656-664 (2012).
33. Dienel GA. Astrocytic energetics during excitatory neurotransmission: What are contributions of glutamate oxidation and glycolysis? Neurochem Int 63(4): 244-258 (2013).
34. Cooper AJ. The role of glutamine synthetase and glutamate dehydrogenase in cerebral ammonia homeostasis. Neurochem Res 37(11): 2439-2455 (2012).
35. Magistretti PJ. Neuron–glia metabolic coupling and plasticity. J Exp Biol 209(12): 2304-2311 (2006).
36. Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, Passarella S. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 497(1): 1-5 (2001).
37. Yang JL, Sykora P, Wilson DM III, Mattson MP, Bohr VA. The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency. Mech Ageing Dev 132(8-9): 405-411 (2011).
38. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634 (1988).
39. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 80: 315-360 (2000).
40. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11(10): 682-696 (2010).
41. Rosenmund C, Feltz A, Westbrook GL. Synaptic NMDA receptor channels have a low open probability. J Neurosci 15: 2788-2795 (1995).
42. Clark BA, Farrant M, Cull-Candy SG. A direct comparison of the single-channel properties of synaptic and extrasynaptic NMDA receptors. J Neurosci 17(1): 107-116 (1997).
43. Rao A, Craig AM. Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. Neuron 19(4): 801-812 (1997).
44. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414 (2002).
45. Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the ERK activity in cultured rat hippocampal neurons. J Physiol 572(3): 789-798 (2006).
46. Leveille F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 22: 4258-4271 (2008).
47. Vanhoutte P, Bading H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol 13(3): 366-371 (2003).
48. Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 29: 9330-9343 (2009).
49. Hardingham GE, Arnold FJ, Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat Neurosci 4: 261-267 (2001).
50. Hardingham GE, Arnold FJ, Bading H. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-tonucleus communication. Nat Neurosci 4: 65-66 (2001).
51. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11: 476-487 (2008).
52. Wu GY, Deisseroth K, Tsien RW. Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 98: 2808-2813 (2001).
53. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 97: 1611-1626 (2006).
54. Chen HS, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, et al. Neuroprotective concentrations of the N-methyl-Daspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86: 1121-1132 (1998).
55. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30: 11246-11250 (2010).
56. Mao P, Reddy PH. Aging and Amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s Disease: Implications for early intervention and therapeutics. Biochim Biophys Acta 1812(11): 1359-1370 (2011).
57. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39: 359-407 (2005).
58. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med 10: 291-315 (2008).
59. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem 96: 1-13 (2006).
60. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 37(8): 1681-1689 (2012).
61. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 408(6809): 239-247 (2000).
62. Serviddio G, Romano AD, Cassano T, Bellanti F, Altomare E, Vendemiale G. Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative disease. Curr Pharm Design 17(20): 2036-2055 (2011).
63. Hroudova J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer’s Disease. Bio-Med Res Int 2014: 175062 (2014).
64. Macario AJ, Cappello F, Zummo G, Conway de Macario E. Chaperonopathies of senescence and the scrambling of interactions between the chaperoning and the immune systems. Ann NY Acad Sci 1197: 85-93 (2010).
65. Walls KC, Coskun P, Gallegos-Perez JL, Zadourian N, Freude K, Rasool S et al. Swedish Alzheimer mutation induces mitochondrial dysfunction mediated by HSP60 mislocalization of amyloid precursor protein (APP) and beta-amyloid. J Biol Chem 287(36): 30317-30327 (2012).
66. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 305: 626-629 (2004).
67. Gunter TE, Sheu SS. Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. Biochim Biophys Acta 1787(11): 1291-308 (2009).
68. Csordas G, Varnai P, Golenar T, Sheu SS, Hajnoczky G. Calcium transport across the inner mitochondrial membrane: Molecular mechanisms and pharmacology. Mol Cell Endocrinol 353: 109-113(2011).
69. Drago I, Pizzo P, Pozzan T. After half a century mitochondrial calcium in-and efflux machineries reveal themselves. EMBO J 30: 4119-4125 (2011).
70. Rai S, Kamat PK, Nath C, Shukla R. A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 254: 1-9 (2013).
71. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci 1: 366-373 (1998).
72. Hunter DR, Haworth RA, Southard JH. Relationship between configuration, function and permeability in calcium-treated mitochondria. J Biol Chem 251: 5069-5077 (1976).
73. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 34: 232-237 (2006).
74. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662 (2005).
75. Shalbuyeva N, Brustovetsky T, Bolshakov A, Brustovetsky N. Calciumdependent spontaneously reversible remodeling of brain mitochondria. J Biol Chem 281: 37547-37558 (2006).
76. De Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. A fortykilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476: 336-340 (2011).
77. Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 476: 341-345 (2011).
78. Somlyo AP, Bond M, Somlyo AV. Calcium content of mitochondria and endoplasmic reticulum in liver frozen rapidly in vivo. Nature 314: 622-625 (1985).
79. Qui J, Tan YW, Hagenston AM, Martel MA, Kneisel N, Skehel PA, et al. Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals. Nat Commun 4: 2034 (2013).
80. Lin Y, Bloodgood BL, Hauser JL, Lapan AD, Koon AC, Kim TK, et al. Activity dependent regulation of inhibitory synapse development by Npas4. Nature 455: 1198-1204 (2008).
81. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460: 525-542 (2010).
82. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9: 1180-1186 (2003).
83. Andrabi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med 17: 692-699 (2011).
84. Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolanos JP. Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ 19: 1582-1589 (2012).
85. O-Uchi J, Pan S, Sheu SS. Perspectives on: SGP symposium on mitochondrial physiology and medicine: molecular identities of mitochondrial Ca2+ influx mechanism: updated passwords for accessing mitochondrial Ca2+-linked health and disease. J Gen Physiol 139(6): 435-443 (2012).
86. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 362: 329-344 (2010).
87. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81(3): 163-221 (1999).
88. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11): 2866-2875 (2007).
89. Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromol Med 4(1-2): 21-36 (2003).
90. Hooper NM. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 33(2): 335-8 (2005).
91. Ohnishi S, Takano K. Amyloid fibrils from the viewpoint of protein folding. Cell Mol Life Sci 61: 511-524 (2004).
92. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8(7): 499-509 (2007).
93. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid 9: 88-102 (2002).
94. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5: 560-564 (1999).
95. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice. Neurobiol Aging 28(9): 1297-1306 (2006).
96. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal β-amyloid aggregates, neurodegeneration and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140 (2006).
97. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39: 409-421 (2003).
98. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 doubletransgenic mice. Neurosci Lett 306: 116-120 (2001).
99. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Aβ. Am J Pathol 168: 184-194 (2006).
100. Gyure KA, Durham R, Stewart W F, Smialek JE, Troncoso JC. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492 (2001).
101. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer’s disease. Neurobiol Aging 10(5): 593-602 (1989).
102. Greenamyre JT, Penney JB, Young AB, D’Amato CJ, Hicks SP, Shoulson I. Alterations in L-glutamate binding in Alzheimer’s and Huntington’s Diseases Science. 227(4693): 1496-1499 (1985).
103. Greenamyre JT. The Role of Glutamate in Neurotransmission and in Neurologic Disease. Arch Neurol 43(10): 1058-1063 (1986).
104. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta 1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
105. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051-1058 (2005).
106. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33: 274-282 (2006).
107. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 32: 802-810 (2011).
108. Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer’s disease. J Neurochem 98: 939-950 (2006).
109. Zoia C, Cogliati T, Tagliabue E, Cavaletti G, Sala G, Galimberti G, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer’s disease. Neurobiol Aging 25: 149-157 (2004).
110. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56: 901-911 (1997).
111. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, et al. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer’s disease. J Neurochem 50: 790-802 (1988).
112. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 28(27): 6926-6937 (2008).
113. Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 105: 584-594 (2008).
114. Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, et al. Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging 33(6): 1121.e1-12 (2012).
115. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Muller WE. Mitochondrial dysfunction in sporadic and genetic Alzheimer’sdisease. Exp Gerontol 41(7): 668-673 (2006).
116. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 21(9): 3017-3023 (2001).
117. Keil U, Bonert A, Marques CA, Scherping I, Wayermann J, Strosznajder JB, et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279(48): 503110-550320 (2004).
118. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol 66(8): 1627-1634 (2003).
119. Lin MT, Beal MF. Alzheimer’s APP mangles mitochondria. Nat Med 12: 1241-1243 (2006).
120. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15: 1437-1449 (2006).
121. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, et al. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 279: 51654-51660 (2004).
122. Chagnon P, Betard Robitaille Y, Cholette A, Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport 6(5): 711-715 (1995).
123. Blass JP. Cerebrometabolic abnormalities in Alzheimer’s dosease. Neurol Res 25(6): 556-566 (2003).
124. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 19(14): 2040-2041 (2005).
125. Henlsey K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91(8): 3270-3274 (1994).
126. Kish, SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, et al. Brain cytochrome oxidase in Alzheimer’s disease. J Neurochem 59(2): 776-779 (1992).
127. Reddy PH. Abnormal Tau, Mitochondrial Dysfunction, Impaired Axonal Transport of Mitochondria, and Synaptic Deprivation in Alzheimer’s Disease. Brain Res 1415: 136-148 (2011).
128. Maurer I, Zierz S, Moller HJ. A selective defect of Cytochrome C Oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21: 455-462 (2000).
129. Muller WE, Kirsch C, Eckert GP. Membrane-disordering effects of beta-amyloid peptides. Biochem Soc Trans 4: 617-623 (2001).
130. Mecocci P, Cherubini A, Beal MF, Cecchetti R, Chionne F, Polidori MC, et al. Altered mitochondria membrane fluidity in AD brain. Neurosci Lett 207: 129-132 (1996).
131. Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord 11: 181-186 (2000).
132. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334: 345-348 (1998).
133. Ansari R, Mahta A, Mallack E, Luo JJ. Kyperhomocysteinemia and neurologic discorde: a Review. J Clin Neurol 10(4): 281-288 (2014).
134. Sanders LH, McCoy J, Hu X, Mastroberardino PG, Dickinson BC, Chang CJ, et al. Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson’s disease. Neurobiol Dis 70: 214-223 (2014).
135. Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Gurini J, Marin C, et al. Functional organization of the basal ganglia: Therapeutic implications for Parkinson’s disease. Mov Disord 23(3): 548-559 (2008).
136. Bou Dib P, Gnagi B, Daly F, Sabado V, Tas D, Glauser DA, et al. A conserved role for p48 homologs in protecting dopaminergic neurons from oxidative stress. PLoS Genet 10(10): e1004718 (2014).
137. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho W, Castillo P, et al. Mice lacking alpha-synucleindisplay functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252 (2000).
138. Yavich L, Tanila H, Vepsalainen S, Jakala P. Role of alphasynuclein in presynaptic dopaminerecruitment. J Neurosci 24: 11165-11170 (2004).
139. Yavich L, Jakala P, Tanila H. Abnormal compart-mentalization of norepinephrine in mousedentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J Neurochem 99: 724-732 (2006).
140. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurol 15: 8053-8061 (2001).
141. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111: 163-169 (2003).
142. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118: 777-788 (2008).
143. Zhou M, Xu S, Mi J, Ueda K, Chan P. Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress. Brain Res 1500: 19-27 (2013).
144. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69(3): 1196-1203 (1997).
145. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, et al. Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154(5): 1423-1429 (1999).
146. Xiang W, Schlachetzki JC, Helling S, Bussmann JC, Berlinghof M, Schaffer TE, et al. Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alphasynuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci 54: 71-83 (2013).
147. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, et al. Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann Neurol 40: 663-671 (1996).
148. Thomas B, Beal MF. Parkinson’s disease. Hum Mol Gen 16(2): R183-194 (2007).
149. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264 (2006).
150. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur J Pharmacol 208: 273-286 (1991).
151. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980 (1983).
152. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkin-sonian subjects. Ann Neurol 42: 261-264 (1997).
153. Parker WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 16: 215-218 (2008).
154. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 115(2): 333-342 (1992).
155. Taylor DJ, Krige D, Barnes PR, Kemp GJ, Carroll MT, Mann VM, et al. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson’s disease J Neurol Sci 125: 77-81 (1994).
156. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32(6): 782-788 (1992).
157. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease, Ann Neurol 37: 714-722 (1995).
158. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14(2): 2749-2755 (2005).
159. Dagda RK, Zhu J, Chu CT. Mitochondrial kinases in Parkinson’s disease: converging insights from neurotoxin and genetic models. Mitochondrion 9(5): 289-298 (2009).
160. Meredith GE, Totterdell S, Beales M, Meshul CK. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol 219: 334-340 (2009).
161. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-Daspartate receptor when intracellular energy levels are reduced. Brain Res 451: 205-212 (1988).
162. Smith ID, Grace AA. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12: 287-303 (1992).
163. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson’s disease. Mol Neurobiol 73-94 (1996).
164. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391-397 (1999).
165. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson’s disease. J Neurochem 63: 1987-1990 (1994).
166. Yue Z, Horton A, Bravin M, DeJager PL, Selimi F, Heintz N. A novel protein complex linking the delta2 glutamate receptor and autophagy: implications for neurodegeneration in lurcher mice. Neuron 35: 921-933 (2002).
167. Takacs-Vellai K, Bayci A, Vellai T. Autophagy in neuronal cell loss: a road to death. Bioessays 28: 1126-1131 (2006).
168. Plaitakis A, Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson’s disease. J Neurol 247: II25-II35 (2000).
169. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7(5): 695-702 (1991).
170. Weissman L, Jo DG, Sorensen MM, de Souza-Pinto NC, Markesbery WR, Mattson MP, et al. Defective DNA base excision repair in brain from individuals with Alzheimer’s disease and amnestic mild cognitive impairment. Nucleic Acids Res 35: 5545-5555 (2007).
171. Blass JP, Sheu RK, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann NY Acad Sci 903: 204-221 (2000).
172. Yao J, Irwin R, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 106(34): 14670-14675 (2009).
173. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100 (2008).
174. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkindeficient mice. J Biol Chem 279: 18614-18622 (2004).
175. Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, et al. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal 14: 341-351 (2011).
176. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H. Mono-and double-mutant mouse models of Parkinson’s disease display severe mitochondrial damage. Hum Mol Genet 16: 2377-2393 (2007).